Two American public health societies provide recommendations on the use of nucleic acid amplification testing (NAAT) to assess patients for pulmonary tuberculosis.
Sponsoring Organizations: The National Tuberculosis Controllers Association and the Association of Public Health LaboratoriesTarget Audience: State and local health departments, hospital epidemiologists, hospital infection preventionists, hospital respiratory therapists, infectious diseases specialists, and hospitalists
Target Population: Hospitalized patients with suspected pulmonary tuberculosis
Background and Objectives
In 2015, the U.S. FDA approved the use of the Cepheid Xpert MTB/RIF (Xpert) assay to assist in determining the need for airborne infection isolation (AII) in patients with suspected pulmonary tuberculosis (TB), on the basis of improved sensitivity and specificity of the assay compared with sputum acid fast bacilli (AFB) smea…
Reviewing Author
DisclosuresConsult/Advisory BoardAcurx Pharmaceuticals, LLC;
Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health
DisclosuresConsult/Advisory BoardAcurx Pharmaceuticals, LLC;
Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health